As of November 4, 2026, LENZ Therapeutics, Inc. is a publicly traded company (Nasdaq: LENZ); its largest reported holder is BlackRock, with 5.8% on Schedule 13G of April 27, 2026, then Fidelity (FMR) (5.7%). The largest insider holding is Versant Vantage II GP, L.P., a 10% owner, with 3,687,254 shares (11.7% of shares outstanding), per Form 4 of October 2, 2025 (Schedule 13G, April 27, 2026).
Is this your company?
About to sign with, pay or invest in LENZ Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is LENZ Therapeutics, Inc. a real, registered company?
- LENZ Therapeutics, Inc. files with the SEC under CIK 1815776 (its SEC filings).
- Its shares are listed under the ticker LENZ on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Solana Beach, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under LENZ THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-04).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-10-28, about 40 jobs).
- Leadership changes: the latest reported is Daniel Chevallard, President (Form 8-K filed 2026-10-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are LENZ Therapeutics, Inc.'s owners and officers?
LENZ Therapeutics, Inc.: incorporated in Delaware; business address in Solana Beach, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13D/A, 2026-11-02).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-02 | Ra Capital Management, L.P. | 0.2% |
| Schedule 13G, 2026-10-27 | Blackrock Portfolio Management LLC | 5.2% |
| Schedule 13G/A, 2026-10-21 | Millennium Management LLC | 3.7% |
| Schedule 13G/A, 2026-09-08 | Fmr LLC | 5.7% |
| Schedule 13G, 2026-06-26 | Millennium Management LLC | 5.1% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 5.8% |
| Schedule 13G, 2026-04-08 | Squarepoint Ops LLC | 5.1% |
| Schedule 13G/A, 2026-02-17 | Ridgeback Capital Investments L.P. | 0% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 11.8% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 4.9% |
| Schedule 13G/A, 2025-11-14 | Paradigm Biocapital Advisors LP | 3.8% |
| Schedule 13G/A, 2025-11-14 | Steven A. Cohen | 4.8% |
Questions about who owns LENZ Therapeutics, Inc.
Who owns LENZ Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of LENZ Therapeutics, Inc.: Blackrock, Inc. (5.8%, Schedule 13G, filed 2026-04-27), Fmr LLC (5.7%, Schedule 13G/A, filed 2026-09-08), Blackrock Portfolio Management LLC (5.2%, Schedule 13G, filed 2026-10-27) and Squarepoint Ops LLC (5.1%, Schedule 13G, filed 2026-04-08).
Who are the largest shareholders of LENZ Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of LENZ Therapeutics, Inc. on this page are Blackrock, Inc. (5.8%), Fmr LLC (5.7%) and Blackrock Portfolio Management LLC (5.2%).
When did Blackrock, Inc. buy into LENZ Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 4.9%; its latest, Schedule 13G filed 2026-04-27, reports 5.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on LENZ Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on LENZ Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LENZ Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-28 | Daniel Chevallard | President | appointed | |
| Form 8-K, 2026-07-02 | Zach Scheiner | departed |
Which insiders own LENZ Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Versant Vantage II GP, L.P., a 10% owner: 3,687,254 shares (11.7% of shares outstanding), 2,101,375 held directly and 1,585,879 indirectly, on a joint filing (Form 4, 2025-10-02).
- Versant Ventures VI GP, L.P., a 10% owner: 3,687,254 shares (11.7% of shares outstanding), 2,101,375 held directly and 1,585,879 indirectly, on a joint filing (Form 4, 2025-10-02).
- Versant Ventures VI GP-GP, LLC, a 10% owner: 3,687,254 shares (11.7% of shares outstanding), 2,101,375 held directly and 1,585,879 indirectly, on a joint filing (Form 4, 2025-10-02).
- , L.P., a 10% owner: 3,687,254 shares (11.7% of shares outstanding), 2,101,375 held directly and 1,585,879 indirectly, on a joint filing (Form 4, 2025-10-02).
- Versant Ventures VII GP, L.P., a 10% owner: 3,687,254 shares (11.7% of shares outstanding), 2,101,375 held directly and 1,585,879 indirectly, on a joint filing (Form 4, 2025-10-02).
Shares outstanding: 31,420,583 as of 2026-10-28, from the company's latest SEC cover page.
How much has LENZ Therapeutics, Inc. raised?
Latest IPO step: LENZ Therapeutics, Inc. filed to go public (S-1, 2024-09-11).
IPO filings: S-1, 2024-09-11; ticker LENZ on Nasdaq Global Select Market.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-10-28).
Keep reading
More on LENZ Therapeutics, Inc. and the records around it.
LENZ Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Jul 2026
Companies that share a holder
- Squarepoint Ops LLC also filed stake reports on 1 other company: Cartesian Therapeutics, Inc. (Mar 2026)
- Ridgeback Capital Investments L.P. also filed stake reports on 3 other companies: Replimune Group, Inc. (Aug 2026), iTeos Therapeutics, Inc. (Nov 2025), Semler Scientific, Inc. (Nov 2025)
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), Monte Rosa Therapeutics, Inc. (Jan 2026), LAVA Therapeutics N.V. (Sep 2025)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lenz-therapeutics